The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin

Wu Yuyan; Shan Tiantian; Pan Xiangtao

doi:doi:10.11648/j.ajcem.20221002.13

| Peer-Reviewed

The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin

Wu Yuyan, Shan Tiantian, Pan Xiangtao

Published in American Journal of Clinical and Experimental Medicine (Volume 10, Issue 2)

Received: 9 April 2022 Accepted: Published: 14 April 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Objective: To research the expression characteristic and clinical significance of the serum bone morphogenetic protein 6 (BMP6) at the lower expression condition of serum C-reactive protein (CRP) and Hepcidin (Hepc) in patients with tumor-related anemia. Methods: 113 hospitalized tumor patients from October 2019 to June 2020 and 20 healthy volunteers (control group) were recruited. We used enzyme-linked immunosorbent assay (ELISA) to determine the levels of BMP6, soluble-hemojuvelin (s-HJV) and Hepc, Electrochemiluminescence method to determine SF level, and particle-enhanced immune transmission turbidity method to determine CRP level, then analyzed their expression characteristics, correlations and clinical significance. Results: (1) The levels of BMP6, Hepc and CRP of anemia group were respectively 426.18±202.83mg/mL, 6.58±5.41ug/L and 19.10±18.24mg/L, which were all higher than 334.37±171.32mg/mL, 4.60±2.28ug/L and 3.62±3.46mg/L of non-anemia group (t=2.5804, 2.4750 and 3.4144, P<0.01, P<0.05 and P<0.01, respectively). (2) The level of s-HJV was 0.71±0.28ng/mL, which was obviously lower than 1.07±1.01ng/mL (t=2.6529, P<0.01) in non-anemia group. (3) There were negative correlations between BMP6 and both Hb and s-HJV (respectively r=-0.2807, t=3.0812 and r=-0.2497, t=2.7230, respectively, P both <0.01), but there were no correlations between BMP6 and CRP, Hepc and SF. (4) Hepc was positively correlated with both CRP and SF (r=0.2004, t=2.0660 and r=0.3089, t=3.1045, P<0.05 and P<0.01, respectively). Hepc was negatively correlated with Hb (r=-0.2524, t=2.7525, P<0.01). Hepc had no correlation with s-HJV (P>0.05). (5) The BMP6 in the normal CRP group was 461.86±142.91 mg/mL, which was significantly higher than 364.51± 129.84 mg/mL in elevated CRP group (F=11.35, P<0.01). (6) Hepc, s-HJV and SF in the normal CRP group were 5.17±3.49ug/L, 0.69±0.26ng/mL and 149.89±142.34ng/mL, respectively, which were all significantly lower than 9.02±7.14ug/L, 0.76±0.33ng/mL and 288.36±254.51ng/mL in the elevated CRP group (F=9.56, 4.67 and 2.84, P=0.000, 0.09, 0.046, respectively). Conclusions: When tumor patients with anemia is in a low-level condition of CRP and Hepc, the high expression of BMP6 is an important cause for the occurrence and development of anemia.

Published in	American Journal of Clinical and Experimental Medicine (Volume 10, Issue 2)
DOI	10.11648/j.ajcem.20221002.13
Page(s)	63-66
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Tumor, Anemia, C-reactive Protein, Bone Morphogenetic Protein 6, Hepcidin

References

[1]	Pan XT, Lu Y, Cheng X, et al. The expression characteristics of Serum Hepcidin and inflammatory mediator cytokine in tumor patients and their relationships with anemia [J]. Journal of Modern Laboratory Medicine, 2011, 26 (4): 22-27.
[2]	Yan M, Cheng X, Lu Y, et al. The relationship of C-reactive protein levels in tumor patients with IL-6 and anemia [J]. China Continuing Medical Education, 2018, 10 (34): 88-90.
[3]	Abdel-Razeq H, & Hashem H. Recent Update in the Pathogenesis and Treatment of Chemotherapy and Cancer Induced Anemia [J]. Critical Reviews in Oncology/Hematology. 2019, 145: 102837.
[4]	Varga E, Pap R, Janosa G, et al. IL-6 Regulates Hepcidin Expression Via the BMP/SMAD Pathway by Altering BMP6, TMPRSS6 and TfR2 Expressions at Normal and Inflammatory Conditions in BV2 Microglia [J]. Neurochem Res. 2021, 46 (5): 1224-1238.
[5]	Shi YJ, Lu Y, Wang JH, et al. Research on the expression characteristics of Neogenin and its relatedness with Hepcidin and SF in patients with tumor-associated anemia [J]. Journal of Modern Laboratory Medicine, 2016, 31 (1): 71-72.
[6]	Cheng Z, Yan M, Lu Y, et al. Expression of serum BMP6 and hepcidin in cancer-related anemia [J]. Hematology. 2020, 25 (1): 134-138.
[7]	Ueda N, & Takasawa K. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease [J]. Nutrients. 2018, 10 (9): 1173.
[8]	Bloomer SA, & Brown KE. Hepcidin and Iron Metabolism in Experimental Liver Injury [J]. Am J Pathol. 2021, 191 (7): 1165-1179.
[9]	Ikeda Y. Novel roles of HIF-PHIs in chronic kidney disease: the link between iron metabolism, kidney function, and FGF23 [J]. Kidney Int. 2021, 100 (1): 14-16.
[10]	Gromadzka G, Wierzbicka D, Litwin T, et al. Iron metabolism is disturbed and anti-copper treatment improves but does not normalize iron metabolism in Wilson's disease [J]. Biometals. 2021, 34 (2): 407-414.
[11]	Shan TT, Cheng Z, Yan M, et al. Analysis on expression characteristics of serum hepcidin and erythropoietin and their relationships with anemia in patients with gastric cancer [J]. Laboratory Medicine and Clinical, 2022, 19 (3): 330-332, 337.
[12]	Suega K, & Widiana GR. Predicting hepcidin level using inflammation markers and iron indicators in patients with anemia of chronic disease [J]. Hematol Transfus Cell Ther. 2019, 41 (4): 342-348.
[13]	Senjo H, Higuchi T, Okada S, et al. Hyperferritinemia: causes and significance in a general hospital [J]. Hematology. 2018, 23 (10): 817-822.
[14]	Silvestri L, Nai A, Dulja A, et al. Hepcidin and the BMP-SMAD pathway: An unexpected liaison [J]. Vitam Horm. 2019, 110: 71-99.
[15]	Banerjee S, Katiyar P, Kumar L, et al. Black pepper prevents anemia of inflammation by inhibiting hepcidin over-expression through BMP6-SMAD1/ IL6-STAT3 signaling pathway [J]. Free Radic Biol Med. 2021, 168: 189-202.
[16]	Xiao X, Alfaro-Magallanes VM, & Babitt JL. Bone morphogenic proteins in iron homeostasis [J]. Bone. 2020, 138: 115495.
[17]	Shi YJ, & Pan XT. BMP6 and BMP4 expression in patients with cancer-related anemia and its relationship with hepcidin and s-HJV [J]. Genet Mol Res. 2016, 15 (1): 15.
[18]	Latour C, Besson-Fournier C, Gourbeyre O, et al. Deletion of BMP6 worsens the phenotype of HJV-deficient mice and attenuates hepcidin levels reached after LPS challenge [J]. Blood. 2017, 130 (21): 2339-2343.
[19]	Enns CA, Ahmed R, Wang J, et al. Increased iron loading induces Bmp6 expression in the non-parenchymal cells of the liver independent of the BMP-signaling pathway [J]. PLoS One. 2013, 8 (4): e60534.
[20]	Fillebeen C, Wilkinson N, Charlebois E, et al. Hepcidin-mediated hypoferremic response to acute inflammation requires a threshold of Bmp6/Hjv/Smad signaling [J]. Blood. 2018, 132 (17): 1829-1841.

Cite This Article

Plain Text BibTeX RIS

APA Style

Wu Yuyan, Shan Tiantian, Pan Xiangtao. (2022). The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin. American Journal of Clinical and Experimental Medicine, 10(2), 63-66. https://doi.org/10.11648/j.ajcem.20221002.13

Copy | Download

ACS Style

Wu Yuyan; Shan Tiantian; Pan Xiangtao. The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin. Am. J. Clin. Exp. Med. 2022, 10(2), 63-66. doi: 10.11648/j.ajcem.20221002.13

Copy | Download

AMA Style

Wu Yuyan, Shan Tiantian, Pan Xiangtao. The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin. Am J Clin Exp Med. 2022;10(2):63-66. doi: 10.11648/j.ajcem.20221002.13

Copy | Download

@article{10.11648/j.ajcem.20221002.13,
  author = {Wu Yuyan and Shan Tiantian and Pan Xiangtao},
  title = {The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {10},
  number = {2},
  pages = {63-66},
  doi = {10.11648/j.ajcem.20221002.13},
  url = {https://doi.org/10.11648/j.ajcem.20221002.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20221002.13},
  abstract = {Objective: To research the expression characteristic and clinical significance of the serum bone morphogenetic protein 6 (BMP6) at the lower expression condition of serum C-reactive protein (CRP) and Hepcidin (Hepc) in patients with tumor-related anemia. Methods: 113 hospitalized tumor patients from October 2019 to June 2020 and 20 healthy volunteers (control group) were recruited. We used enzyme-linked immunosorbent assay (ELISA) to determine the levels of BMP6, soluble-hemojuvelin (s-HJV) and Hepc, Electrochemiluminescence method to determine SF level, and particle-enhanced immune transmission turbidity method to determine CRP level, then analyzed their expression characteristics, correlations and clinical significance. Results: (1) The levels of BMP6, Hepc and CRP of anemia group were respectively 426.18±202.83mg/mL, 6.58±5.41ug/L and 19.10±18.24mg/L, which were all higher than 334.37±171.32mg/mL, 4.60±2.28ug/L and 3.62±3.46mg/L of non-anemia group (t=2.5804, 2.4750 and 3.4144, PPPt=2.6529, Pr=-0.2807, t=3.0812 and r=-0.2497, t=2.7230, respectively, P both r=0.2004, t=2.0660 and r=0.3089, t=3.1045, PPr=-0.2524, t=2.7525, PP>0.05). (5) The BMP6 in the normal CRP group was 461.86±142.91 mg/mL, which was significantly higher than 364.51± 129.84 mg/mL in elevated CRP group (F=11.35, PF=9.56, 4.67 and 2.84, P=0.000, 0.09, 0.046, respectively). Conclusions: When tumor patients with anemia is in a low-level condition of CRP and Hepc, the high expression of BMP6 is an important cause for the occurrence and development of anemia.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin
AU  - Wu Yuyan
AU  - Shan Tiantian
AU  - Pan Xiangtao
Y1  - 2022/04/14
PY  - 2022
N1  - https://doi.org/10.11648/j.ajcem.20221002.13
DO  - 10.11648/j.ajcem.20221002.13
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 63
EP  - 66
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20221002.13
AB  - Objective: To research the expression characteristic and clinical significance of the serum bone morphogenetic protein 6 (BMP6) at the lower expression condition of serum C-reactive protein (CRP) and Hepcidin (Hepc) in patients with tumor-related anemia. Methods: 113 hospitalized tumor patients from October 2019 to June 2020 and 20 healthy volunteers (control group) were recruited. We used enzyme-linked immunosorbent assay (ELISA) to determine the levels of BMP6, soluble-hemojuvelin (s-HJV) and Hepc, Electrochemiluminescence method to determine SF level, and particle-enhanced immune transmission turbidity method to determine CRP level, then analyzed their expression characteristics, correlations and clinical significance. Results: (1) The levels of BMP6, Hepc and CRP of anemia group were respectively 426.18±202.83mg/mL, 6.58±5.41ug/L and 19.10±18.24mg/L, which were all higher than 334.37±171.32mg/mL, 4.60±2.28ug/L and 3.62±3.46mg/L of non-anemia group (t=2.5804, 2.4750 and 3.4144, PPPt=2.6529, Pr=-0.2807, t=3.0812 and r=-0.2497, t=2.7230, respectively, P both r=0.2004, t=2.0660 and r=0.3089, t=3.1045, PPr=-0.2524, t=2.7525, PP>0.05). (5) The BMP6 in the normal CRP group was 461.86±142.91 mg/mL, which was significantly higher than 364.51± 129.84 mg/mL in elevated CRP group (F=11.35, PF=9.56, 4.67 and 2.84, P=0.000, 0.09, 0.046, respectively). Conclusions: When tumor patients with anemia is in a low-level condition of CRP and Hepc, the high expression of BMP6 is an important cause for the occurrence and development of anemia.
VL  - 10
IS  - 2
ER  -

Copy | Download

Author Information

Wu Yuyan

Department of Hematology, Taicang Hospital Affiliated to Suchow University, Taicang, China
Shan Tiantian

Department of Hematology, Taicang Hospital Affiliated to Suchow University, Taicang, China
Pan Xiangtao

Department of Hematology, Taicang Hospital Affiliated to Suchow University, Taicang, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Wu Yuyan, Shan Tiantian, Pan Xiangtao. (2022). The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin. American Journal of Clinical and Experimental Medicine, 10(2), 63-66. https://doi.org/10.11648/j.ajcem.20221002.13

Copy | Download

ACS Style

Wu Yuyan; Shan Tiantian; Pan Xiangtao. The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin. Am. J. Clin. Exp. Med. 2022, 10(2), 63-66. doi: 10.11648/j.ajcem.20221002.13

Copy | Download

AMA Style

Wu Yuyan, Shan Tiantian, Pan Xiangtao. The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin. Am J Clin Exp Med. 2022;10(2):63-66. doi: 10.11648/j.ajcem.20221002.13

Copy | Download

@article{10.11648/j.ajcem.20221002.13,
  author = {Wu Yuyan and Shan Tiantian and Pan Xiangtao},
  title = {The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {10},
  number = {2},
  pages = {63-66},
  doi = {10.11648/j.ajcem.20221002.13},
  url = {https://doi.org/10.11648/j.ajcem.20221002.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20221002.13},
  abstract = {Objective: To research the expression characteristic and clinical significance of the serum bone morphogenetic protein 6 (BMP6) at the lower expression condition of serum C-reactive protein (CRP) and Hepcidin (Hepc) in patients with tumor-related anemia. Methods: 113 hospitalized tumor patients from October 2019 to June 2020 and 20 healthy volunteers (control group) were recruited. We used enzyme-linked immunosorbent assay (ELISA) to determine the levels of BMP6, soluble-hemojuvelin (s-HJV) and Hepc, Electrochemiluminescence method to determine SF level, and particle-enhanced immune transmission turbidity method to determine CRP level, then analyzed their expression characteristics, correlations and clinical significance. Results: (1) The levels of BMP6, Hepc and CRP of anemia group were respectively 426.18±202.83mg/mL, 6.58±5.41ug/L and 19.10±18.24mg/L, which were all higher than 334.37±171.32mg/mL, 4.60±2.28ug/L and 3.62±3.46mg/L of non-anemia group (t=2.5804, 2.4750 and 3.4144, PPPt=2.6529, Pr=-0.2807, t=3.0812 and r=-0.2497, t=2.7230, respectively, P both r=0.2004, t=2.0660 and r=0.3089, t=3.1045, PPr=-0.2524, t=2.7525, PP>0.05). (5) The BMP6 in the normal CRP group was 461.86±142.91 mg/mL, which was significantly higher than 364.51± 129.84 mg/mL in elevated CRP group (F=11.35, PF=9.56, 4.67 and 2.84, P=0.000, 0.09, 0.046, respectively). Conclusions: When tumor patients with anemia is in a low-level condition of CRP and Hepc, the high expression of BMP6 is an important cause for the occurrence and development of anemia.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin
AU  - Wu Yuyan
AU  - Shan Tiantian
AU  - Pan Xiangtao
Y1  - 2022/04/14
PY  - 2022
N1  - https://doi.org/10.11648/j.ajcem.20221002.13
DO  - 10.11648/j.ajcem.20221002.13
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 63
EP  - 66
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20221002.13
AB  - Objective: To research the expression characteristic and clinical significance of the serum bone morphogenetic protein 6 (BMP6) at the lower expression condition of serum C-reactive protein (CRP) and Hepcidin (Hepc) in patients with tumor-related anemia. Methods: 113 hospitalized tumor patients from October 2019 to June 2020 and 20 healthy volunteers (control group) were recruited. We used enzyme-linked immunosorbent assay (ELISA) to determine the levels of BMP6, soluble-hemojuvelin (s-HJV) and Hepc, Electrochemiluminescence method to determine SF level, and particle-enhanced immune transmission turbidity method to determine CRP level, then analyzed their expression characteristics, correlations and clinical significance. Results: (1) The levels of BMP6, Hepc and CRP of anemia group were respectively 426.18±202.83mg/mL, 6.58±5.41ug/L and 19.10±18.24mg/L, which were all higher than 334.37±171.32mg/mL, 4.60±2.28ug/L and 3.62±3.46mg/L of non-anemia group (t=2.5804, 2.4750 and 3.4144, PPPt=2.6529, Pr=-0.2807, t=3.0812 and r=-0.2497, t=2.7230, respectively, P both r=0.2004, t=2.0660 and r=0.3089, t=3.1045, PPr=-0.2524, t=2.7525, PP>0.05). (5) The BMP6 in the normal CRP group was 461.86±142.91 mg/mL, which was significantly higher than 364.51± 129.84 mg/mL in elevated CRP group (F=11.35, PF=9.56, 4.67 and 2.84, P=0.000, 0.09, 0.046, respectively). Conclusions: When tumor patients with anemia is in a low-level condition of CRP and Hepc, the high expression of BMP6 is an important cause for the occurrence and development of anemia.
VL  - 10
IS  - 2
ER  -

Copy | Download